Activity Overview
This educational activity is an archive of the live presentation held on July 16, 2026.
Target Audience
This educational activity is directed toward retina specialists, ophthalmologists, optometrists, and other eye care professionals involved in the care of patients with geographic atrophy.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the role of complement system dysregulation in the onset and progression of GA.
- Implement findings from advanced imaging modalities to identify and monitor GA.
- Apply evidence-based criteria to guide the initiation of complement inhibitor therapy in appropriate patients with GA.
SriniVas R. Sadda, MD, FARVO
A. Ray Irvine, Jr, MD, Endowed Chair in Clinical Ophthalmology
Professor of Ophthalmology
David Geffen School of Medicine at UCLA
Director of Artificial Intelligence & Imaging Research, Doheny
Eye Institute
Pasadena, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AAvantgarde, AbbVie/Allergan, Alexion, Alkeus, Alnylam, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Character, EyePoint, Eyestem, Heidelberg, iCare/CenterVue, Ikerian, Iveric Bio/Astellas, Janssen, Nanoscope, Neurotech, Notal Vision, Novartis, Ocular Therapeutix, ONL Therapeutics, Optos, Pfizer, Regeneron, Regenxbio, Roche/Genentech, Samsung Bioepis, Surrozen, Topcon; Grant/Research Funding (to institution): Carl Zeiss Meditec, Heidelberg, iCare, Intalight, Nidek, Optos, Topcon
Hong-Uyen Hua, MD
Assistant Professor of Clinical Ophthalmology
University of Miami Miller School of Medicine
Bascom Palmer Eye Institute
Miami, FL
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Alcon, ANI, Apellis, EyePoint; Speakers Bureau: Amgen
Adrienne W. Scott, MD, FASRS
Fred M. Leader Family Retina Professor of Ophthalmology
Professor of Ophthalmology
Johns Hopkins University School of Medicine
Wilmer Eye Institute (Medical Director, Wilmer Bel Air Clinic)
Bel Air, MD
Disclosures: Advisor, Consultant, Fee for Service Recipient: 4D, Adverum, Alcon, Apellis, Astellas, Bayer, Boehringer Ingelheim, Disc Medicine, EyePoint, Genentech/Roche, Ocular Therapeutix, Oculis, Regeneron; Grant/Research Funding: Genentech/Roche, Optos, Regeneron
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
